Radicava

E561112

Radicava is a prescription medication containing edaravone, used to slow the progression of amyotrophic lateral sclerosis (ALS) in adults.

Try in SPARQL Jump to: Surface forms Statements Referenced by

Observed surface forms (1)

Surface form Occurrences
Radicava ORS 0

Statements (47)

Predicate Object
instanceOf brand name drug
oral suspension formulation of edaravone
prescription medication
administrationSetting healthcare facility
approvedBy U.S. Food and Drug Administration NERFINISHED
ATCCode N07XX11
commonAdverseEffect contusion
eczema
gait disturbance
headache
respiratory discomfort
containsExcipient sodium bisulfite
contraindication history of hypersensitivity to edaravone
countryOfApproval United States NERFINISHED
dosageForm solution for intravenous infusion
firstApprovalYear 2017
hasActiveIngredient edaravone NERFINISHED
edaravone NERFINISHED
hasAlternativeBrand Radicava ORS NERFINISHED
hasBoxedWarning hypersensitivity reactions including anaphylaxis
hasBrandName Radicava NERFINISHED
hasFormulation intravenous formulation
hasGenericName edaravone NERFINISHED
hasManufacturer Mitsubishi Tanabe Pharma NERFINISHED
Mitsubishi Tanabe Pharma America, Inc. NERFINISHED
indication slow progression of functional decline in ALS
indicationPopulation ALS patients with mild to moderate functional impairment
indicationType disease-modifying treatment for ALS
isNotIndicatedFor pediatric patients
legalStatus prescription only
mechanismOfAction reduces oxidative stress by scavenging free radicals
pharmacologicalClass antioxidant
pregnancyCategory use only if potential benefit justifies potential risk
regimenCharacteristic cyclic dosing schedule
requiresMonitoring respiratory status during infusion
signs of hypersensitivity
routeOfAdministration intravenous infusion
oral
storageCondition store at controlled room temperature
targetPopulation adult patients
therapeuticClass free radical scavenger
neuroprotective agent
treats ALS in adults
amyotrophic lateral sclerosis
amyotrophic lateral sclerosis in adults
warning risk of anaphylaxis
risk of hypersensitivity reactions

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

edaravone hasBrandName Radicava
subject surface form: Edaravone